Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00592111 · ClinicalTrials.gov registry record · Phase 2

A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)

A Phase 2 study of Hodgkin's Disease and Pediatric, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
Phase 2
Development phase
21
Enrollment target
1
Study location

NCT00592111: Completed Phase 2 study of Hodgkin's Disease and Pediatric, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00592111 is a Phase 2 study of Hodgkin's Disease and Pediatric that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 21 participants, below the 237-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00592111, a Phase 2 study of Hodgkin's Disease and Pediatric, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
Phase 2
Development phase
21 participants
Enrollment target
1
Study location

Study Summary

Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.

Interventions

  • DRUG COPP/ABV
  • DRUG intensive chemo with concurrent growth factor

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 21 participants
Start Date 1996-03
Est. Completion 2008-01
Phase Phase 2
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00592111 record still lists

NCT00592111 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 237-participant average among 20 other Hodgkin's Disease trials with a reported enrollment target (91% lower).

The record links to 2 conditions, with Hodgkin's Disease appearing as the primary indexed condition, and to 2 interventions - of which COPP/ABV is the first listed.

NCT00592111 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00592111 about?

NCT00592111 is a clinical study titled "A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942)". Study Hypothesis: Clinical staging without laparotomy/splenectomy is adequate for children and young adults with Hodgkin's disease who receive chemotherapy as a component of treatment.

What is the current status of trial NCT00592111?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 1996-03. Estimated completion is 2008-01.

What conditions does trial NCT00592111 study?

This clinical trial studies the following conditions: Hodgkin's Disease, Pediatric.

What interventions are being tested in trial NCT00592111?

The interventions under investigation include: COPP/ABV (DRUG), intensive chemo with concurrent growth factor (DRUG).

Who is sponsoring clinical trial NCT00592111?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00592111 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hodgkin's Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00592111's enrollment target sits among peer trials

21 16th of 20 higher than 4 of 20 other Hodgkin's Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hodgkin's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02447874 · 21 participants · Phase 1

    Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease

  • NCT03826992 · 21 participants · Phase 1

    Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia

  • NCT04107077 · 21 participants · Phase 2

    Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer

  • NCT04158635 · 21 participants · Phase 1

    Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00592111, the US trial registry maintained by the National Library of Medicine. NCT00592111 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.